▲ +79.71% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Aptose Biosciences in the last 3 months. The average price target is $11.29, with a high forecast of $16.00 and a low forecast of $9.00. The average price target represents a 79.71% upside from the last price of $6.28.
The current consensus among 7 contributing investment analysts is to buy stock in Aptose Biosciences. This Buy consensus rating has held steady for over two years.
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.